Central Circle Company ("CCC") was first established in 1979, specifically to provide medical equipment and turnkey solutions for various medical institutions in the State of Kuwait.  CCC's main objective, subsequent to the acquisition is to promote ethical transparency, innovation and excellence within the medical industry. Dr. Ziad Alalyan, a Consultant and Fellow of the College of Emergency Medicine and Member of the Royal College of Surgeons, UK and Scotland, was appointed as Partner and Chief Executive Officer (“CEO”) of CCC in 2014, following its acquisition by the Senior Partner and Dr. Alalyan. During his short tenure as CEO, Dr. Alalyan has taken CCC to the upper echelons of the medical industry, coupled with a veracious appetite for global expansion and excellence. CCC has experienced significant growth in all sectors, specifically in pharmaceutical products.  The management however, are now exploring other avenues of enhancing the services CCC offers to end-users i.e. utilising Artificial Intelligence (“AI”) to generate automated medical services.  The company also has ambitious plans to venture into independent healthcare centres, with a primary emphasis on offering complete medical services i.e. diagnosis, operative procedures, follow up and after care.  Lastly, the majority of staff at CCC are medical professionals, fostering an environment that promotes ethical transparency, hard work and talent, resulting in an amalgamation of unique distinction.  Secondly, CCC encourages sustained end-user interaction, edifying CCC as to strategies required to adapt to the needs of the same.  Finally, the sound welfare of the end-user is a responsibility that is weaved into the rhetoric of the company policy, a legacy that CCC would like to leave for generations to come. Notable achievements for CCC include appointments with Abbott, Astra Zeneca, Boston Scientific, Draeger, Johnson and Johnson, KCI, Phillips, Roche, Sanofi and many more.